首页> 外文期刊>European journal of cardio-thoracic surgery: Official journal of the European Association for Cardio-thoracic Surgery >Non-small cell lung cancer with single brain metastasis: the role of surgical treatment.
【24h】

Non-small cell lung cancer with single brain metastasis: the role of surgical treatment.

机译:非小细胞肺癌伴单脑转移:手术治疗的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: The prognosis of non-small cell lung cancer (NSCLC) with brain metastasis is very poor, with median survival rate below 6 months, even if treated with palliative radio and/or chemotherapy. To assess the effectiveness of surgical treatment for this kind of patients we reviewed our experience. METHODS: From January 1989 to October 1999, 30 patients (26 males and four females; mean age: 58.7 years) with NSCLC and single brain metastasis underwent surgical treatment of both primary lung cancer and secondary cerebral lesion. Patients (pts) were divided into two major groups. In group 1 (G1) 20 pts (18 males and two females) presented a synchronous brain metastasis. In group 2 (G2) 10 pts (eight males and two females) presented a metachronous brain metastasis during the follow-up period (range 3-24 months since the primary tumor). Patients selected in G1 had T1-2, N0-1 clinical staging, good 'performance status' (ECOG:0--1; Karnofsky index > 70%), age < 75 years. Craniotomy has always been the first approach. In G2 also patients with locally advanced tumors (T3 and/or N2) were included. Whole brain radiotherapy and/or chemotherapy was the post-operative choice treatment. RESULTS: Histologic findings have shown: adenocarcinoma in 17 cases (12 in G1; five in G2), squamous cell carcinoma in 10 cases (six in G1; four in G2), large cell carcinoma in 2 (one in G1; one in G2) and large cell neuroendocrine carcinoma in one (G1). Survival analysis (Kaplan--Meier method) has shown an overall value of 80% at 1 year (95% in G1; 50% in G2), 41% at 2 years (47% in G1; 30% in G2) and 17% at 3 years (14% in G1; 20% in G2). Overall median survival is 23 months (23 in G1; 11 in G2); mean survival 27.8 months (30.3 months in G1; 22.8 months in G2). According to univariate analysis prognosis is definitively better in N0 tumors compared to N1-2 tumors and in adenocarcinoma cases compared to other histotypes (P < 0.05). CONCLUSIONS: We can conclude that combined surgical therapy is, nowadays, the choice treatment for this kind of patients, even though restricted to selected cases. The knowledge of prognostic factors may optimize indications for surgery.
机译:目的:即使接受姑息性放疗和/或化疗,非小细胞肺癌伴脑转移的预后也很差,中位生存期低于6个月。为了评估对这类患者进行手术治疗的有效性,我们回顾了我们的经验。方法:从1989年1月至1999年10月,对30例NSCLC并伴有单发脑转移的NSCLC患者进行了手术治疗,包括原发性肺癌和继发性脑病变。患者(点)分为两个主要组。在第1组(G1)中,有20分(男18例,女2例)出现同步性脑转移。在第2组(G2)中,在随访期间(自原发肿瘤后3-24个月),有10分(8名男性和2名女性)出现了异时性脑转移。在G1中选择的患者具有T1-2,N0-1临床分期,良好的“表现状态”(ECOG:0--1; Karnofsky指数> 70%),年龄<75岁。开颅手术一直是第一种方法。在G2中,还包括具有局部晚期肿瘤(T3和/或N2)的患者。全脑放疗和/或化疗是术后的选择治疗。结果:组织学结果显示:腺癌17例(G1中12例; G2中5例),鳞状细胞癌10例(G1中6例; G2中4例),大细胞癌2例(G1中1例; G2中1例)。 )和大细胞神经内分泌癌合二为一(G1)。生存分析(Kaplan-Meier方法)显示1年总价值为80%(G1为95%; G2为50%),2年41%(G1为47%; G2为30%)和17 3年时的百分比(G1中为14%; G2中为20%)。总体中位生存期为23个月(G1为23; G2为11);平均生存27.8个月(G1为30.3个月; G2为22.8个月)。根据单因素分析,与N1-2肿瘤相比,N0肿瘤的预后肯定更好,与其他组织类型相比,在腺癌病例中的预后更好(P <0.05)。结论:我们可以得出结论,即使限于特定病例,联合手术治疗是当今这类患者的选择治疗。预后因素的知识可以优化手术适应症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号